StockData
Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc. (COGT) stock

COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$27.85+0.41 (+1.49%)

Close on Nov 17, 2026Market cap $4.83BP/E –Yield –

Cogent Biosciences total assets

Total assets on the balance sheet at the end of each period.

Cogent Biosciences's total assets was $834.55M at Jun 30, 2026. For fiscal 2025 it was $937.61M, up 185.9% from the year before. The highest annual figure on record is $937.61M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$937.61M+185.9%
FY2024Dec 31, 2024$327.90M+4.6%
FY2023Dec 31, 2023$313.44M+4.2%
FY2022Dec 31, 2022$300.81M+29.6%
FY2021Dec 31, 2021$232.09M-7.5%
FY2020Dec 31, 2020$250.92M+407.7%
FY2019Dec 31, 2019$49.42M-42.5%
FY2018Dec 31, 2018$85.93M+75.0%
FY2017Dec 31, 2017$49.12M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$834.55M+203.7%
Q1 FY2026Mar 31, 2026$903.01M+218.2%
Q4 FY2025Dec 31, 2025$937.61M+185.9%
Q3 FY2025Sep 30, 2025$425.93M+10.9%
Q2 FY2025Jun 30, 2025$274.82M-36.1%
Q1 FY2025Mar 31, 2025$283.80M-40.4%
Q4 FY2024Dec 31, 2024$327.90M+4.6%
Q3 FY2024Sep 30, 2024$384.02M+8.0%
Q2 FY2024Jun 30, 2024$429.94M+9.6%
Q1 FY2024Mar 31, 2024$476.11M+80.9%
Q4 FY2023Dec 31, 2023$313.44M+4.2%
Q3 FY2023Sep 30, 2023$355.45M+7.2%
Q2 FY2023Jun 30, 2023$392.37M+7.2%
Q1 FY2023Mar 31, 2023$263.20M+27.2%
Q4 FY2022Dec 31, 2022$300.81M+29.6%
Q3 FY2022Sep 30, 2022$331.56M+53.9%
Q2 FY2022Jun 30, 2022$366.05M+60.2%
Q1 FY2022Mar 31, 2022$206.87M-12.9%
Q4 FY2021Dec 31, 2021$232.09M-7.5%
Q3 FY2021Sep 30, 2021$215.39M+54.0%
Q2 FY2021Jun 30, 2021$228.52M+635.8%
Q1 FY2021Mar 31, 2021$237.61M+510.2%
Q4 FY2020Dec 31, 2020$250.92M+407.7%
Q3 FY2020Sep 30, 2020$139.87M+141.6%
Q2 FY2020Jun 30, 2020$31.06M-55.2%
Q1 FY2020Mar 31, 2020$38.94M-52.1%
Q4 FY2019Dec 31, 2019$49.42M-42.5%
Q3 FY2019Sep 30, 2019$57.88M-38.9%
Q2 FY2019Jun 30, 2019$69.31M-32.5%
Q1 FY2019Mar 31, 2019$81.28M+87.2%
Q4 FY2018Dec 31, 2018$85.93M+75.0%
Q3 FY2018Sep 30, 2018$94.79M–
Q2 FY2018Jun 30, 2018$102.72M–
Q1 FY2018Mar 31, 2018$43.42M–
Q4 FY2017Dec 31, 2017$49.12M–

More Cogent Biosciences figures

See a number that looks wrong?